Is Xilio Therapeutics, Inc. (XLO) a Buy, Sell, or Hold?
NASDAQ : XLO
Xilio Therapeutics, Inc. — Institutional Ownership
$8.87 USD
-$0.31 (-3.38%)
- Volume
- 7.12K
- Average Volume
- 43.68K
- Market Capitalization
- $58.32M
- P/E Ratio
- -5.95
- Dividend Yield
- 0.00%
- Price Target
- $98.00
- Year High
- $12.74
- Year Low
- $6.47
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.25
Institutional Ownership Summary
Institutional Ownership %
%
Investors Holding
change: 0.0 | last:
Increased Positions
change: 0.0 | last:
Reduced Positions
change: 0.0 | last:
New Positions
change: 0.0 | last:
Sold Positions
change: 0.0 | last:
Total Calls
-
Total Puts
-
Put-Call Ratio
change: 0.0 | last:
Total Invested
-
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-15 | ORBIMED ADVISORS LLC | 642K | 9.99% |
| 2026-05-15 | BCLS II Equity Opportunities, LP | 664.02K | 9.99% |
| 2026-05-15 | Point72 Asset Management, L.P. | - | 0.00% |
| 2026-05-15 | Sirenia Capital Management LP | 1.14M | 9.90% |
| 2026-02-17 | Bain Capital Life Sciences Fund II, L.P. | 992.11K | 1.30% |
| 2026-02-17 | StemPoint Capital LP | 6.03M | 8.40% |
| 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 4.68M | 6.70% |
| 2026-02-12 | GILEAD SCIENCES, INC. | 14.52M | 19.90% |
| 2025-12-11 | Coastlands Capital LP | 5.35M | 9.99% |
| 2025-11-14 | StemPoint Capital LP | 4M | 7.20% |
| 2025-11-14 | Point72 Asset Management, L.P. | 8M | 9.90% |
| 2025-08-14 | GILEAD SCIENCES, INC. | 10.61M | 19.90% |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 8.14M | 9.90% |
| 2025-06-17 | Point72 Asset Management, L.P. | 4M | 7.20% |
| 2025-06-12 | Frazier Life Sciences Public Fund, L.P. | 3.51M | 6.30% |
| 2025-05-15 | Rock Springs Capital Management LP | - | 0.00% |
| 2025-02-18 | AbbVie Inc. | 4.35M | 9.00% |
| 2024-09-27 | Yekaterina Chudnovsky | 7M | 15.90% |
| 2024-09-27 | Yekaterina Chudnovsky | 7M | 15.90% |
| 2024-09-27 | GKCC, LLC | 7M | 15.90% |
| 2024-09-27 | GKCC, LLC | 7M | 15.90% |
| 2024-04-05 | Gilead Sciences, Inc. | 7.35M | 19.90% |
| 2024-02-14 | Rock Springs Capital LLC | 1.44M | 5.23% |
| 2024-02-14 | Rock Springs Capital LLC | 1.44M | 5.23% |
| 2024-02-14 | Rock Springs Capital Management LP | 1.44M | 5.23% |
| 2024-02-14 | Rock Springs Capital Management LP | 1.44M | 5.23% |
| 2023-04-10 | MRL Ventures Fund, LLC | 1.48M | 5.40% |
| 2023-04-10 | MRL Ventures Fund, LLC | 1.48M | 5.40% |
| 2023-04-10 | Merck Sharp & Dohme Corp. | 1.48M | 5.40% |
| 2023-04-10 | Merck & Co., Inc. | 1.48M | 5.40% |
| 2023-04-10 | Merck & Co., Inc. | 1.48M | 5.40% |
| 2023-04-10 | Merck Sharp & Dohme Corp. | 1.48M | 5.40% |
| 2023-01-25 | OCTAGON CAPITAL ADVISORS LP | 2.42M | 8.83% |
| 2023-01-25 | TING JIA | 2.42M | 8.83% |
| 2023-01-25 | TING JIA | 2.42M | 8.83% |
| 2023-01-25 | OCTAGON INVESTMENTS MASTER FUND LP | 2.42M | 8.83% |
| 2023-01-25 | OCTAGON CAPITAL ADVISORS LP | 2.42M | 8.83% |
| 2023-01-25 | OCTAGON INVESTMENTS MASTER FUND LP | 2.42M | 8.83% |
| 2022-11-14 | RA Capital Healthcare Fund, L.P. | - | 0.00% |
| 2022-11-14 | Rajeev Shah | - | 0.00% |
| 2022-11-14 | RA Capital Management, L.P. | - | 0.00% |
| 2022-11-14 | Peter Kolchinsky | - | 0.00% |
| 2022-11-14 | RA Capital Healthcare Fund, L.P. | - | 0.00% |
| 2022-11-14 | Rajeev Shah | - | 0.00% |
| 2022-11-14 | RA Capital Management, L.P. | - | 0.00% |
| 2022-11-14 | Peter Kolchinsky | - | 0.00% |
| 2022-01-14 | Takeda Pharmaceutical Company Limited | 1.48M | 5.37% |
| 2022-01-14 | Takeda Ventures, Inc. | 1.48M | 5.37% |
| 2021-11-05 | Ph.D. | 1.44M | 5.40% |
| 2021-11-05 | Atlas Venture Associates XI, L.P. | 2.02M | 7.60% |
| 2021-11-05 | Atlas Venture Associates XI, LLC | 2.02M | 7.60% |
| 2021-11-05 | Atlas Venture Fund XI, L.P. | 2.02M | 7.60% |
| 2021-11-05 | L.P. | 1.44M | 5.40% |
| 2021-11-05 | L.P. | 1.44M | 5.40% |
| 2021-11-05 | Jay Schmelter | 1.44M | 5.40% |
| 2021-11-05 | L.P. | 1.44M | 5.40% |
| 2021-11-05 | L.P. | 1.44M | 5.40% |
| 2021-11-05 | LLC | 1.44M | 5.40% |
| 2021-11-05 | Bain Capital Life Sciences Fund II, L.P. | 1.35M | 5.10% |
| 2021-11-05 | BCLS II Investco, LP | 1.25M | 4.70% |
| 2021-11-05 | BCIP Life Sciences Associates, LP | 164.26K | 0.60% |
| 2021-11-05 | BCLS II Investco, LP | 1.25M | 4.70% |
| 2021-11-05 | Bain Capital Life Sciences Fund II, L.P. | 1.35M | 5.10% |
| 2021-11-05 | BCIP Life Sciences Associates, LP | 164.26K | 0.60% |
| 2021-11-05 | Atlas Venture Opportunity Fund I, L.P. | 735.94K | 2.80% |
| 2021-11-05 | Atlas Venture Associates Opportunity I, LLC | 735.94K | 2.80% |
| 2021-11-05 | LLC | 1.44M | 5.40% |
| 2021-11-05 | John P. McKearn, Ph.D | 1.44M | 5.40% |
| 2021-11-05 | RA Capital Management, L.P. | 1.53M | 5.70% |
| 2021-11-05 | Peter Kolchinsky | 1.53M | 5.70% |
| 2021-11-05 | Rajeev Shah | 1.53M | 5.70% |
| 2021-11-05 | Atlas Venture Associates Opportunity I, L.P. | 735.94K | 2.80% |
| 2021-11-05 | Ph.D. | 1.44M | 5.40% |
| 2021-11-05 | John P. McKearn, Ph.D | 1.44M | 5.40% |
| 2021-11-05 | Jay Schmelter | 1.44M | 5.40% |
| 2021-11-05 | RA Capital Management, L.P. | 1.53M | 5.70% |
| 2021-11-05 | Peter Kolchinsky | 1.53M | 5.70% |
| 2021-11-05 | Atlas Venture Associates Opportunity I, L.P. | 735.94K | 2.80% |
| 2021-11-05 | Atlas Venture Associates Opportunity I, LLC | 735.94K | 2.80% |
| 2021-11-05 | Atlas Venture Fund XI, L.P. | 2.02M | 7.60% |
| 2021-11-05 | Atlas Venture Associates XI, L.P. | 2.02M | 7.60% |
| 2021-11-05 | Atlas Venture Associates XI, LLC | 2.02M | 7.60% |
| 2021-11-05 | Atlas Venture Opportunity Fund I, L.P. | 735.94K | 2.80% |
| 2021-11-05 | Rajeev Shah | 1.53M | 5.70% |
| 2021-11-05 | RA Capital Healthcare Fund, L.P. | 1.36M | 5.10% |
| 2021-11-05 | RA Capital Healthcare Fund, L.P. | 1.36M | 5.10% |
| 2021-11-04 | FMR LLC | 2.66M | 9.97% |
| 2021-11-04 | Abigail P. Johnson | 2.66M | 9.97% |
| 2021-11-04 | FMR LLC | 2.66M | 9.97% |
| 2021-11-04 | Abigail P. Johnson | 2.66M | 9.97% |
| 2021-11-03 | SV7 Impact Medicine Fund LP | 1.61M | 6.05% |
| 2021-11-03 | SV7 (IMF) GP LLP | 1.61M | 6.05% |
| 2021-11-03 | SV7 (IMF) GP LLP | 1.61M | 6.05% |
| 2021-11-03 | SV7 Impact Medicine Fund LP | 1.61M | 6.05% |
| 2021-10-27 | Deerfield Mgmt V, L.P. | 1.14M | 4.29% |
| 2021-10-27 | Deerfield Mgmt, L.P. | 1.14M | 4.29% |
| 2021-10-27 | Deerfield Private Design Fund V, L.P. | 1.14M | 4.29% |
| 2021-10-27 | Deerfield Partners, L.P. | 1.14M | 4.29% |
| 2021-10-27 | Deerfield Mgmt V, L.P. | 1.14M | 4.29% |
| 2021-10-27 | Deerfield Private Design Fund V, L.P. | 1.14M | 4.29% |
| 2021-10-27 | Company, L.P. | 2.29M | 8.58% |
| 2021-10-27 | James E. Flynn | 2.29M | 8.58% |
| 2021-10-27 | Company, L.P. | 2.29M | 8.58% |
| 2021-10-27 | Deerfield Mgmt, L.P. | 1.14M | 4.29% |
| 2021-10-27 | James E. Flynn | 2.29M | 8.58% |
| 2021-10-27 | Deerfield Partners, L.P. | 1.14M | 4.29% |
XLO Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $8.96 | 83.59M | $748.98M | $137.53M | $6.95M | $618.4M |
| 2024-12-31 | $13.37 | 3.82M | $51.1M | $55.29M | $8.14M | $3.95M |
| 2023-12-31 | $7.70 | 1.96M | $15.12M | $44.7M | $12.5M | -$17.08M |
| 2022-12-31 | $37.66 | 1.96M | $73.68M | $120.38M | $19.94M | -$26.76M |
| 2021-12-31 | $224.00 | 400.45K | $89.7M | $198.05M | $20.74M | -$87.62M |
| 2020-12-31 | $224.00 | 37413 | $8.38M | $19.24M | $21.89M | $11.03M |
| 2019-12-31 | $224.00 | 29235 | $6.55M | $48.84M | $18.63M | -$23.67M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9.58 | 194.05M | $1.86B | $136.04M | $6.3M | $1.73B |
| 2026-03-31 | $8.41 | 163.48M | $1.37B | $150.33M | $6.64M | $1.23B |
| 2025-12-31 | $8.96 | 83.59M | $748.98M | $137.53M | $6.95M | $618.4M |
| 2025-09-30 | $11.80 | 10.29M | $121.46M | $103.76M | $7.26M | $24.96M |
| 2025-06-30 | $9.52 | 3.7M | $35.24M | $121.55M | $7.57M | -$78.74M |
| 2025-03-31 | $10.14 | 5.34M | $54.1M | $89.07M | $7.86M | -$27.1M |
| 2024-12-31 | $13.37 | 4.62M | $61.77M | $55.29M | $8.14M | $14.62M |
| 2024-09-30 | $11.03 | 4.53M | $50M | $61.26M | $8.42M | -$2.84M |
| 2024-06-30 | $12.93 | 3.14M | $40.59M | $74.95M | $8.68M | -$25.67M |
| 2024-03-31 | $21.42 | 1.99M | $42.71M | $33.98M | $8.94M | $17.67M |
| 2023-12-31 | $7.70 | 1.97M | $15.16M | $44.7M | $11.46M | -$18.09M |
| 2023-09-30 | $29.54 | 1.97M | $58.08M | $59.77M | $14.39M | $12.69M |